Who is sponsoring NCT05375474?

NCT05375474 is sponsored by China National Center for Cardiovascular Diseases.

What drugs are being tested in NCT05375474?

Interventions in NCT05375474: Oral anticoagulation therapy, Single antiplatelet therapy.

What condition does NCT05375474 study?

NCT05375474 studies Transcatheter Aortic Valve Replacement, Antithrombotic Therapy, Bioprosthetic Valve Thrombosis.

Is NCT05375474 still recruiting?

NCT05375474 is currently status unknown. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT05375474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

Status unknown Phase 4 Last updated 23 October 2023

What this trial tests

Phase 4 trial testing Oral anticoagulation therapy in Transcatheter Aortic Valve Replacement in 650 participants. Status unknown.

Timeline

27 July 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	China National Center for Cardiovascular Diseases
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	650
Start date	27 July 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Oral anticoagulation therapy — full drug profile →
Single antiplatelet therapy — full drug profile →

Conditions studied

Transcatheter Aortic Valve Replacement — all drugs for Transcatheter Aortic Valve Replacement →
Antithrombotic Therapy — all drugs for Antithrombotic Therapy →
Bioprosthetic Valve Thrombosis — all drugs for Bioprosthetic Valve Thrombosis →

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Adults 18 to 85, any sex, with Transcatheter Aortic Valve Replacement or Antithrombotic Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, randomized controlled study meant to test the superior efficacy of oral anticoagulation (OAC) therapy versus single antiplatelet therapy (SAPT) in patients after TAVR. Patients who accept successful TAVR will be randomized to receive either the OAC group (Vitamin-K antagonists) or the SAPT group (aspirin) for 6 months on a 1:1 ratio. After that, patients from both groups will be treated with single antiplatelet therapy (aspirin). All patients will be followed for 1 year to test the difference between net clinical benefits and bioprosthetic valve thrombosis diagnosed by 4D-CT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.
Hu X, Xu H, Wang C, Wang Y, et al · · 2023 · cited 1× · PMID 37989381 · DOI 10.1136/bmjopen-2023-076781

Verify or expand the search:

Other trials of Oral anticoagulation therapy

Trials testing the same drug.

NCT03838341 — Stand-alone Totally Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip® Device in Non-valvular Atrial Fibrilla · unknown

Other recruiting trials for Transcatheter Aortic Valve Replacement

Currently open trials in the same condition.

NCT06559332 — Coronary Artery Disease Assessment Strategies in TAVI Patients · NA · recruiting
NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
NCT06420830 — Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis. · recruiting
NCT05758701 — CT TAVR Abdomen Study · Phase 4 · recruiting
NCT06000943 — Ischemic And Bleeding Risk Assessment After TAVR · recruiting

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05375474 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05375474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing